4-(Diethylaminomethyl)benzoyl chloride | 80335-46-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(Diethylaminomethyl)benzoyl chloride
• 英文别名: 4-((diethylamino)methyl)benzoyl chloride；α-diethylamino-paratoluic acid chloride；4-Diethylaminomethylbenzoyl chloride；Benzoyl chloride, 4-((diethylamino)methyl)-
• CAS: 80335-46-2
• 化学式: C₁₂H₁₆ClNO
• 分子量: 225.718
• InChiKey: NYYCMPNJBMCAJT-UHFFFAOYSA-N

物化性质

• 沸点：
  290.8±23.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(Diethylaminomethyl)benzoyl chloride 在 sodium azide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-((diethylamino)methyl)benzoyl azide
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001
• 作为产物：
  描述：

  4-乙氨基甲基苯甲酸 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-(Diethylaminomethyl)benzoyl chloride
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001

文献信息

• Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity
  申请人：Vial Henri

  公开号：US06972343B1

  公开（公告）日：2005-12-06

  The invention concerns drug precursors with antimalarial effect, characterised in that it consists in quaternary bis-ammonium salts of general formula (I) wherein A and A′, identical or different, are respectively either a group A1 and A′1 of formula (1) wherein n=2 to 4; R′1 is hydrogen, C1-C5 alkyl, optionally substituted by an aryl, a hydroxy, an alkoxy, wherein the alkyl comprises 1 to 5 C, or aryloxy and W is halogen or a nucleofuge group; or a group A2 which represents formyl-CHO, or acetyl-COCH3. B and B′, identical or different, represent respectively either the group B1 and B′1, if A and A′ respectively represent A1, A′1, B1, B′1 representing a group R1 which has the same definition as R′1 above, but cannot be a hydrogen atom; or respectively the groups B2 and B′2, if A and A′ represent A2, B2 or B′2 being the group R1 as defined above, or a group of formula (2) wherein —Ra is RS— or RCO—, wherein R is a C1-C6 alkyl, substituted if required, a phenyl or benzyl, wherein the phenyl is substituted if required, the latter being optionally substituted; R2 is hydrogen, C1-C5 alkyl, or a —CH2-COO— (C1-C5)alkyl group; and R3 is hydrogen, C1-C5 alkyl or alkenyl, substituted if required, a phosphate, an alkoxy wherein the alkyl is a C1-C3 alkyl, or aryloxy; or an alkyl (or arylcarbonyloxy; or R2 and R3 form together a cycle with 5 or 6 C; R and R3 can be bound to form a cycle. ± represents: either a single bond when A and A′ represent A1 and A′1: or when A and A′ represent A2, and B2 and B′2 Represent (3) either, when A and A′ are —CHO or —COCH3 and B2 and B′2 are R1, a group of formula (4) or a group of formula (5) wherein (a) represents a bond towards Z and (b) a bond towards the nitrogen atom. Z is a C9-C21 alkyl, if required with insertion of one or several bonds, and/or one or several heteroatoms O and/or S and/or several aromatic cycles, and the pharmaceutically acceptable salts of said compounds. Said precursors and cyclized thiazolium derivatives are useful as antiparasitic medicines in particular antimalarial and antibabesiosis.

  该发明涉及具有抗疟疾作用的药物前体，其特征在于它由通式(I)的季铵双盐组成，其中A和A′，相同或不同，分别是通式(1)的A1和A′1基团，其中n=2至4；R′1是氢，C1-C5烷基，可选地被芳基、羟基、烷氧基（其中烷基包括1至5个碳）、芳氧基取代，W是卤素或亲核离去基；或者是代表甲酰基-CHO或乙酰基-COCH3的A2基团。B和B′，相同或不同，分别代表A和A′分别表示A1、A′1、B1、B′1的情况下的B1和B′1基团，其中B1、B′1代表与上述R′1相同定义的R1基团，但不能是氢原子；或者分别代表A和A′表示A2的情况下的B2和B′2基团，其中B2或B′2是如上定义的R1基团，或者是通式(2)的基团，其中-Ra是RS-或RCO-，其中R是C1-C6烷基，必要时取代，苯基或苄基，其中苯基在必要时取代，后者是可选地取代的；R2是氢、C1-C5烷基，或者是—CH2-COO-(C1-C5)烷基；R3是氢、C1-C5烷基或烯烃基，必要时取代，磷酸酯、烷氧基（其中烷基是C1-C3烷基）或芳氧基；或者是烷基（或芳基羰基氧基；或者R2和R3共同形成一个含有5或6个碳的环；R和R3可以结合形成一个环。±表示：当A和A′表示A1和A′1时，是单键；或者当A和A′表示A2，B2和B′2表示(3)时，当A和A′为—CHO或—COCH3，B2和B′2为R1时，是通式(4)的基团或通式(5)的基团，其中(a)表示朝向Z的键，(b)表示朝向氮原子的键。Z是C9-C21烷基，必要时插入一个或多个键，和/或一个或多个杂原子O和/或S，和/或几个芳香环，以及所述化合物的药学上可接受的盐。所述前体和环化噻唑衍生物作为抗寄生虫药物，特别是抗疟疾和抗巴贝斯病的药物是有用的。
• Pyrazolopyridines and pyrazolopyridazines as antidabetics
  申请人：——

  公开号：US20040019052A1

  公开（公告）日：2004-01-29

  The present invention includes compound of formula (I), 1 or a derivative thereof, wherein Y is CH or N; R 1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclyl and the alkyl moieties may each independently be unsubstituted or substituted; and R 2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention includes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

  本发明包括式(I)的化合物或其衍生物，其中Y是CH或N；R1是未取代或取代的烷基，未取代或取代的环烷基，未取代或取代的烯基，未取代或取代的环烯基，未取代或取代的芳基，芳基烷基，其中芳基和烷基基团各自可以独立地未取代或取代，芳基烯基，其中芳基和烯基基团各自可以独立地未取代或取代，未取代或取代的杂环基，或杂环基烷基，其中杂环基和烷基基团各自可以独立地未取代或取代；以及R2是未取代的芳基或未取代或取代的杂芳基。此外，本发明还包括制备这种化合物的方法，含有这种化合物的药物组合物，以及这种化合物在医学上的用途。
• Unsymmetrical cyanine dyes and their application
  申请人：Ying Laiqiang

  公开号：US09850382B1

  公开（公告）日：2017-12-26

  The invention describes the preparation and use of fluorescent stains for nucleic acids derived from unsymmetrical cyanine dyes. The dyes of the invention possess superior fluorescent properties when complexed with nucleic acids, and have utility in any application which requires detection of nucleic acids, such as detection of nucleic acids in solution, in gels, in blots, in microarrays, and in bacteria and cells, and for use in analysis of cell structure, membrane integrity, and function. The dyes of the invention have the formula where X is O, S, or C(CH3)2; Each of R1 and R6 is independently hydrogen, carboxy, sulfo, sulfonamide, halogen, CN, or alkoxy; Each of t and s is an integer from 0 to 4; R2 is an alkyl, or alkyl group substituted by a carboxy, or a sulfo; R3 is H, C6H4CO2R7, or C6H4CH2N(R7)2, where R7 is an alkyl; R4 is H, alkyl, aryl, halogen, alkoxy, alkylamino, or alkylthio; R5 is an alkyl, aryl, alkyl group substituted by a carboxy, or a sulfo, or —(CH2)a—[O—(CH2)b]m—O—Z, where Z is H, alkyl, or carboxy; each of a and b is an integer from 1 to 4; m is an integer selected from 0 to 4.

  该发明描述了从非对称靛蓝染料中衍生的核酸荧光染料的制备和使用。该发明的染料在与核酸形成复合物时具有优越的荧光性能，并在任何需要检测核酸的应用中具有实用性，例如在溶液中检测核酸、在凝胶中检测核酸、在印迹中检测核酸、在微阵列中检测核酸、在细菌和细胞中检测核酸，并用于细胞结构、膜完整性和功能的分析。该发明的染料具有下列结构式：其中X为O、S或C(CH3)2；R1和R6中的每一个独立地为氢、羧基、磺酸基、磺酰胺基、卤素、CN或烷氧基；t和s各自为0到4的整数；R2为烷基或通过羧基或磺酸基取代的烷基基团；R3为H、C6H4CO2R7或C6H4CH2N(R7)2，其中R7为烷基；R4为H、烷基、芳基、卤素、烷氧基、烷基氨基或烷基硫基；R5为烷基、芳基、通过羧基或磺酸基取代的烷基基团，或—(CH2)a—[O—(CH2)b]m—O—Z，其中Z为H、烷基或羧基；a和b各自为1到4的整数；m为从0到4选取的整数。
• 不对称花青素染料及其应用
  申请人：安迪福诺生物科技（武汉）有限公司

  公开号：CN108440987A

  公开（公告）日：2018-08-24

  本发明提出了一种不对称花青素染料结构的化合物，具有化学结构通式(I)。该化合物本身没有荧光，但与RNA复合时可以产生强烈的荧光信号，并且荧光信号强度与RNA浓度成正比，且对RNA具有高度选择性。因此，利用该化合物可以简单快速测定生物样品中RNA的浓度。
• PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS
  申请人：Garland Stephen

  公开号：US20060223800A1

  公开（公告）日：2006-10-05

  The present invention includes compound of formula (I), or a derivative thereof wherein Y is CH or N; R 1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclcyl and the alkyl moieties may each inedepently be unsubstituted or substituted; and R 2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention inlcudes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

  本发明涉及式（I）的化合物或其衍生物，其中Y为CH或N；R1为未取代或取代的烷基，未取代或取代的环烷基，未取代或取代的烯基，未取代或取代的环烯基，未取代或取代的芳基，芳基烷基，其中芳基和烷基部分各自可以独立地未取代或取代，芳基烯基，其中芳基和烯基部分各自可以独立地未取代或取代，未取代或取代的杂环基或杂环基烷基，其中杂环基和烷基部分各自可以独立地未取代或取代；以及R2为未取代的芳基或未取代或取代的杂芳基。此外，本发明还包括制备此类化合物的方法，含有此类化合物的药物组合物以及在医学上使用此类化合物的用途。